DOCSLIB.ORG

August 14, 2019 Docket Nos. FDA-1975-N-0012

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
August 14, 2019 Docket Nos. FDA-1975-N-0012 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 August 14, 2019 Docket Nos. FDA-1975-N-0012; FDA-2015-N-0101; and FDA-2016-N-0124 American Cleaning Institute Attention: Richard Sedlak Executive Vice President, Technical and International Affairs 1331 L Street, NW, Suite 650 Washington, DC 20005 Re: Benzalkonium Chloride, Benzethonium Chloride, Chloroxylenol, Ethanol, and Povidone- Iodine Dear Mr. Sedlak: This letter responds to American Cleaning Institute’s (ACI’s) March 12, 2019 request: (1) for a renewal of the extension of the deferral from final rulemaking under the OTC Drug Review on benzalkonium chloride, benzethonium chloride, chloroxylenol, ethanol, and povidone-iodine for use in nonprescription (often referred to as over-the-counter or OTC) consumer antiseptic wash, health care antiseptic, and consumer antiseptic rub drug products. In March 2016, FDA issued letters granting requests to defer three active ingredients—benzalkonium chloride, benzethonium chloride, and chloroxylenol—from inclusion in the final rulemaking for the December 2013 proposed rule for OTC consumer antiseptic washes (78 FR 76444). Similarly, in January 2017, FDA issued letters granting requests to defer six active ingredients—benzalkonium chloride, benzethonium chloride, chloroxylenol, ethanol, povidone-iodine, and isopropyl alcohol—from inclusion in the final rulemaking for the May 2015 proposed rule for OTC health care antiseptics (80 FR 25166). In October 2017, FDA issued letters granting requests to defer three active ingredients— benzalkonium chloride, ethanol, and isopropyl alcohol—from inclusion in the final rulemaking for the June 2016 proposed rule for OTC consumer rub antiseptics (81 FR 42912). In April 2018, FDA granted an extension to defer final rulemaking on these five active ingredients-- benzalkonium chloride, benzethonium chloride, chloroxylenol, ethanol, and povidone-iodine--under the antiseptic rulemakings, and granted ACI’s request to harmonize into a single document and reporting cycle the timing for deferrals of these five active ingredients among the various antiseptic rulemakings for which it has requested deferrals. As explained in each of the deferral letters, FDA deferred inclusion of these active ingredients from each of the respective rulemakings for one year, subject to renewal, to allow more time for completion of the studies necessary to demonstrate safety and effectiveness. FDA also stated, however, that “if no such studies have been commenced, or if the studies in progress do not appear, in FDA’s judgment, to be productive, the agency expects that it will proceed to rulemaking for [the] ingredient[s] after [the] initial deferral[s].” ACI submitted its statements of intent to fill the safety and effectiveness data gaps for benzalkonium chloride, benzethonium chloride, chloroxylenol, ethanol, and povidone-iodine under the antiseptic rulemaking proceedings for use in OTC consumer antiseptic washes, consumer antiseptic rubs, and health care antiseptic products, for certain specified indications. To date, ACI has submitted multiple reports demonstrating its ongoing progress in conducting the necessary safety and efficacy studies (see April 12, 2018 FDA Extension Deferral Letter). On March 12, 2019, ACI submitted its most recent progress report and provided reference to the following updated information in support of its progress in fulfilling the data gaps: (1) A February 15, 2019 final report (#150941-202) for the active ingredients benzalkonium chloride, benzethonium chloride, chloroxylenol, povidone-iodine and ethanol entitled “Determination of the Minimum Inhibitory Concentrations (MIC) and Minimum Bacterial Concentrations (MBC) of Five Test Materials” (currently pending FDA’s feedback); (2) A February 26, 2019 response to comments and questions contained in FDA’s Advice letter dated July 5, 2018 regarding the time-kill study final report (#150940-201) for the active ingredients benzalkonium chloride, benzethonium chloride, chloroxylenol, and ethanol; (3) A final report on the ethanol efficacy study submitted as part of the Briefing Package for the March 1, 2018 Meeting with FDA. A draft pivotal protocol (applicable to ethanol for health care personnel and consumer hand rub) has been developed and its implementation is currently pending the identification of a second clinical laboratory qualified to conduct the study. The final protocol will be submitted to FDA prior to study start-up; (4) Research conducted to: 1) assess whether there are significant dermal absorption differences among the marketed formulas of consumer antiseptic hand wash products, and 2) identify a product type having the greatest dermal penetration of the actives benzalkonium chloride and benzethonium chloride in liquid, bar, and foaming formulations. Consequently, final reports (#39290 and #39479) were submitted for in vitro dermal penetration studies of benzalkonium chloride and benzethonium chloride for the Feedback Meeting on May 9, 2018. This information will be used to define the number of hand hygiene events in a pilot maximal use trial 2 (MUsT) for health care antiseptic products containing benzalkonium chloride, benzethonium chloride, chloroxylenol, ethanol and povidone-iodine; (5) A draft pilot MUsT study protocol (“A Pilot Maximal Use Study to Measure the Systemic Absorption of Benzalkonium Chloride (BAC) After Exaggerated Use of the Antimicrobial Soap on Intact Skin in Healthy Volunteers”) submitted for FDA review and feedback at the meeting on May 9, 2018; (6) A search effort seeking qualification of a second laboratory to conduct the full range of pivotal in vivo studies for benzalkonium chloride, chloroxylenol, ethanol and povidone-iodine. Performance evaluation at candidate laboratories in 2018 failed to identify a second laboratory qualified to conduct the studies. Additional efforts are continuing to address/correct issues identified during qualification audits and to identify additional candidate laboratories; (7) A final report on the observational studies (for benzalkonium chloride and benzethonium chloride) submitted for FDA’s review under the Feedback Meeting of May 9, 2018 in regard to the MUsT program. This information will be used to define the maximum number of washes in a proposed pilot MUsT for consumer antiseptic hand wash products containing benzalkonium chloride, benzethonium chloride, and chloroxylenol. (8) A meeting with FDA on August 6, 2018 to obtain review feedback on the Enterotoxigenic Escherichia coli (ETEC; strain H10407) (ETEC) challenge study protocol (proposed foodborne induction model for consumer hand wash products) and the Skin Infection Model for consumer hand wash products, focusing on clinical outcome study design elements based on FDA’s April 3, 2017 Advice Letter and follow-up studies. These studies would generate data for benzalkonium chloride, benzethonium chloride, and chloroxylenol; (9) A revised ethanol maximal usage trial (MUsT) protocol (supporting formulation permeation data and additional information on bioanalytical method development submitted to FDA for review on July 13, 2017) to address comments received from FDA in an Advice letter dated August 6, 2018. FDA has reviewed the information that ACI has submitted thus far in support of its progress to demonstrate safety and effectiveness for benzalkonium chloride, benzethonium chloride, chloroxylenol, ethanol, and povidone-iodine. Based on this review, FDA grants another extension to defer final rulemaking on these five active ingredients under the antiseptic rulemakings. The extension to defer final rulemaking on the five active ingredients shall be for one year from the date of this letter, subject to renewal. A report describing ACI’s specific progress on all ongoing studies for these five active ingredients is to be submitted to FDA by July14, 2020. We note that ACI’s March 2019 progress report is missing the status and milestones for some of the in vivo efficacy studies for the active ingredients povidone iodine and benzethonium chloride for certain health care antiseptic indications. Although ACI has indicated that reduced funding and limitations in laboratory testing capacity have made it difficult to identify a reliable time schedule for these studies, an estimated timeline is necessary for awareness and a consistent assessment of expectations and is to be provided. In addition, ACI has indicated that it will no longer be working on studies for the health care 3 personnel hand wash indication for the active ingredient benzethonium chloride because of reduced funding. As we have stated in previous correspondence, in order for FDA to continue to grant deferrals of final rulemaking for the respective active ingredients, it is important for sponsors to demonstrate that progress has been made for each study. This includes a commitment to conduct the applicable studies within a reasonable timetable. FDA requests to meet with ACI to discuss these issues in more detail. The Agency acknowledges ACI’s commitment to generating the necessary safety and effectiveness data, and understands that ACI is also requesting “assurances for longer term market access” in the form of a multiyear deferral. FDA declines to grant a multiyear deferral, but assuming ACI continues to make progress in its ongoing studies, the Agency anticipates that future extensions of the deferral may be granted. Although FDA remains fully committed to working with sponsors throughout the extent of this process, the Agency
Load more

Recommended publications
  • Comparison of Effectiveness Disinfection of 2%
    ORIGINAL RESEARCH Journal of Dentomaxillofacial Science (J Dentomaxillofac Sci ) December 2018, Volume 3, Number 3: 169-171 P-ISSN.2503-0817, E-ISSN.2503-0825 Comparison of effectiveness disinfection of 2% Original Research glutaraldehyde and 4.8% chloroxylenol on tooth extraction instruments in the Department of Oral CrossMark http://dx.doi.org/10.15562/jdmfs.v3i2.794 Maxillofacial Surgery, Faculty of Dentistry, University of North Sumatera Month: December Ahyar Riza,* Isnandar, Indra B. Siregar, Bernard Volume No.: 3 Abstract Objective: To compare disinfecting effectiveness of 2% glutaraldehyde while the control group was treated with 4.8% chloroxylenol. Each Issue: 2 and 4.8% chloroxylenol on tooth extraction instruments at the instrument was pre-cleaned using a brush, water and soap for both Department of Oral Surgery, Faculty of Dentistry, University of North groups underwent the disinfection process. Sumatera. Results: The results were statistically analyzed using Mann-Whitney Material and Methods: This was an experimental study with post- Test. The comparison between glutaraldehyde and chloroxylenol First page No.: 147 test only control group design approach. Purposive technique is showed a significant difference to the total bacteria count on applied to collect samples which are lower molar extraction forceps. In instrument after disinfection (p=0.014 < 0.05). this study, sample were divided into 2 groups and each consisting of 18 Conclusion: 2% glutaraldehyde was more effective than 4.8% P-ISSN.2503-0817 instruments. The treatment group was treated with 2% glutaraldehyde chloroxylenol at disinfecting lower molar extraction forceps. Keyword: Disinfection, Glutaraldehyde, Chloroxylenol, Forceps E-ISSN.2503-0825 Cite this Article: Riza A, Siregar IB, Isnandar, Bernard.
    [Show full text]
  • Comparative Analysis of Chlorhexidine Gluconate, Povidone Iodine and Chloroxylenol As Scrubbing Solution
    British Journal of Pharmacology and Toxicology 1(2): 93-95, 2010 ISSN: 2044-2467 © Maxwell Scientific Organization, 2010 Submitted date: May 20, 2010 Accepted date: August 21, 2010 Published date: November 15, 2010 Comparative Analysis of Chlorhexidine Gluconate, Povidone Iodine and Chloroxylenol as Scrubbing Solution 1A.S. Yakubu, 1A.A. Abubakar, 2M.D. Salihu, 1A. Jibril and 1I. Isah 1Department of Veterinary Medicine, Surgery and Theriogenology 2Department of Veterinary Public Health and Preventive Medicine, Usmanu Danfodiyo University, Sokoto Abstract: The study was carried out to determine the efficacy of stock concentration of the commonly used disinfectant as scrub solution for surgical site in goats. The evaluation of efficacy and safety of commercially available disinfectant and antiseptic (0.3% Chlorhexidine gluconate, 0.4% Chloroxylenol and 4% Povidone iodine) as scrub solution for surgical site, using stock concentration was assessed in thirty (30) Red Sokoto goats undergoing non elective surgical procedures at Usmanu Danfodiyo University, Veterinary Teaching Hospital and Zonal Veterinary Clinic, Sokoto. Colony counting was used to quantify skin bacteria Colony Forming Unit (CFU) at surgical site before and after skin preparation. Reduction of CFU before and after preparation was significant with all the three disinfectants compared (p<0.05) and the result shows that Povidone iodine and Chloroxylenol to be less effecacious than Chlorhexidine gluconate when mean colony forming unit after two minute of preparing the surgical sites.
    [Show full text]
  • Disinfection of Tonometers a Report by the American Academy of Ophthalmology
    Ophthalmic Technology Assessment Disinfection of Tonometers A Report by the American Academy of Ophthalmology Anna K. Junk, MD,1 Philip P. Chen, MD,2 Shan C. Lin, MD,3 Kouros Nouri-Mahdavi, MD,4 Sunita Radhakrishnan, MD,5 Kuldev Singh, MD, MPH,6 Teresa C. Chen, MD7 Objective: To examine the efficacy of various disinfection methods for reusable tonometer prisms in eye care and to highlight how disinfectants can damage tonometer tips and cause subsequent patient harm. Methods: Literature searches were conducted last in October 2016 in the PubMed and the Cochrane Library databases for original research investigations. Reviews, non-English language articles, nonophthalmology articles, surveys, and case reports were excluded. Results: The searches initially yielded 64 unique citations. After exclusion criteria were applied, 10 labo- ratory studies remained for this review. Nine of the 10 studies used tonometer prisms and 1 used steel discs. The infectious agents covered in this assessment include adenovirus 8 and 19, herpes simplex virus (HSV) 1 and 2, human immunodeficiency virus 1, hepatitis C virus, enterovirus 70, and variant Creutzfeldt-Jakob disease. All 4 studies of adenovirus 8 concluded that after sodium hypochlorite (dilute bleach) disinfection, the virus was undetectable, but only 2 of the 4 studies found that 70% isopropyl alcohol (e.g., alcohol wipes or soaks) eradicated all viable virus. All 3 HSV studies concluded that both sodium hypochlorite and 70% isopropyl alcohol eliminated HSV. Ethanol, 70% isopropyl alcohol, dilute bleach, and mechanical cleaning all lack the ability to remove cellular debris completely, which is necessary to prevent prion transmission. Therefore, single-use tonometer tips or disposable tonometer covers should be considered when treating patients with suspected prion disease.
    [Show full text]
  • Nomination Background: N-(3-Chloroallyl)Hexaminium Chloride
    • NATIONAL TOXICOLOGY PROGRAM EXECUTIVE SUMMARY OF SAFETY AND TOXICITY INFORMATION N-(3-CHLOROALLYL)HEXAMINIUM CHLORIDE CAS Number 4080-31-3 July 16, 1991 Submitted to: NATIONAL TOXICOLOGY PROGRAM Submitted by: Arthur D. Little, Inc. Chemical Evaluation Committee Draft Report • • TABLE OF CONTENTS Page L NOMINATION HISTORY AND REVIEW .................... 1 II. CHEMICAL AND PHYSICAL DATA ....................... 3 III. PRODUCTION/USE ................................... 5 IV. EXPOSURE/REGULATORY STATUS...................... .10 V. TOXICOLOGICAL EFFECTS ........................... .11 VI. STRUCTURE ACTIVITY RELATIONSHIPS ..................48 VII. REFERENCES ..................................... : . ......... 49 APPENDIX I, ON-LINE DATA BASES SEARCHED ............ .53 APPENDIX II, SAFETY INFORMATION.................... .54 1 ,, .• • • OVERVJEWl Nomination History: N-(3-Chloroallyl)hexaminium chloride was originally nominated for carcinogenicity testing by the National Cancer Institute (NCI) in 1980 with moderate priority. In March 1980, the Chemical Evaluation Committee (CEC) recommended carcinogenicity testing. Due to budgetary cutbacks in 1982, this compound was reevaluated and recommended for in vitro cytogenetics and chemical disposition testing by the CEC, and was selected for chemical disposition testing by the Executive Committee. The renomination of this chemical in 1984 by the NCI was based on potentialfor significant human exposure and concern that it may be carcinogenic due to structural considerations. This recent nomination was
    [Show full text]
  • Disinfection and Sterilization
    Disinfection and Sterilization William A. Rutala, Ph.D., M.P.H. University of North Carolina (UNC) Health Care System and UNC at Chapel Hill, NC Disinfection and Sterilization z HICPAC Guideline z Provide overview of disinfection and sterilization principles z Emerging pathogens and prions z Current Research Clostridium difficile Ophthalmic equipment (applanation tonometers) Infrared coagulation Microfiber mops Computer keyboards QUAT absorption Failure to follow disinfection/sterilization principles and patient exposures 1 disinfectionandsterilization.org Disinfection and Sterilization in Healthcare Facilities WA Rutala, DJ Weber, and HICPAC, “In press” z Overview Last CDC guideline in 1985 274 pages (>130 pages preamble, 21 pages recommendations, glossary of terms, tables/figures, >1000 references) Evidence-based guideline Cleared by HICPAC February 2003 Reviewed by OMB Publication in December 2006 2 Efficacy of Disinfection/Sterilization Influencing Factors Cleaning of the object Organic and inorganic load present Type and level of microbial contamination Concentration of and exposure time to disinfectant/sterilant Nature of the object Temperature and relative humidity 3 Disinfection and Sterilization EH Spaulding believed that how an object will be disinfected depended on the object’s intended use. CRITICAL - objects which enter normally sterile tissue or the vascular system or through which blood flows should be sterile. SEMICRITICAL - objects that touch mucous membranes or skin that is not intact require a disinfection process (high-level disinfection [HLD]) that kills all microorganisms but high numbers of bacterial spores. NONCRITICAL -objects that touch only intact skin require low-level disinfection. 4 Processing “Critical” Patient Care Objects Classification: Critical objects enter normally sterile tissue or vascular system, or through which blood flows.
    [Show full text]
  • Disinfectant and Antiseptics Pdf
    Disinfectant and antiseptics pdf Continue Antiseptics and disinfectants are very similar in that they are both used to kill microorganisms. They differ from each other, albeit in the composition of them, as well as their use. Antiseptics are used on living organisms, such as human skin, to kill any microorganisms living on the surface of the body. Disinfectants are used on non-living things such as countertops and handrails to kill microorganisms living on this inanimate surface. Antiseptics tend to have a lower concentration of a particular biocide, which is used in this product to clean the surface than that of a disinfectant. Since disinfectants are not intended for use on living tissues, but rather inanimate surfaces, they can use a higher concentration of biocide in the product, since there is no skin or tissue to worry about irritants. Antiseptics require a lower concentration of biocides, as too high concentrations of some biocides can cause a large amount of skin irritation. Some examples of antiseptics are mouthwash or hand sanitizer, both of which are safe for contact with your skin and also capable of being extremely effective in killing large numbers of microorganisms. Alcohol, bleach and formaldehyde are examples of various types of disinfectants used to kill microorganisms on the surface of any non-living objects. It is important that people know the difference between antiseptics and disinfectants, as they are both used for similar things, but in different ways. The use of disinfectant as an antiseptic is likely to irritate this tissue. In addition, the use of antiseptic as a disinfectant may result in less sufficient work to clean this surface due to the lower concentration of the biocide.
    [Show full text]
  • Environmental Health Criteria 242
    INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY Environmental Health Criteria 242 DERMAL EXPOSURE IOMC INTER-ORGANIZATION PROGRAMME FOR THE SOUND MANAGEMENT OF CHEMICALS A cooperative agreement among FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization The International Programme on Chemical Safety (IPCS) was established in 1980. The overall objec- tives of the IPCS are to establish the scientific basis for assessment of the risk to human health and the environment from exposure to chemicals, through international peer review processes, as a prerequi- site for the promotion of chemical safety, and to provide technical assistance in strengthening national capacities for the sound management of chemicals. This publication was developed in the IOMC context. The contents do not necessarily reflect the views or stated policies of individual IOMC Participating Organizations. The Inter-Organization Programme for the Sound Management of Chemicals (IOMC) was established in 1995 following recommendations made by the 1992 UN Conference on Environment and Development to strengthen cooperation and increase international coordination in the field of chemical safety. The Participating Organizations are: FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and OECD. The purpose of the IOMC is to promote coordination of the policies and activities pursued by the Participating Organizations, jointly or separately, to achieve the sound management of chemicals in relation to human health and the environment. WHO Library Cataloguing-in-Publication Data Dermal exposure. (Environmental health criteria ; 242) 1.Hazardous Substances - poisoning.
    [Show full text]
  • Assessment of the Antibiotic Resistance Effects of Biocides
    Scientific Committee on Emerging and Newly Identified Health Risks SCENIHR Assessment of the Antibiotic Resistance Effects of Biocides The SCENIHR adopted this opinion at the 28th plenary on 19 January 2009 after public consultation. 1 Antibiotic Resistance Effects of Biocides About the Scientific Committees Three independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat. They are: the Scientific Committee on Consumer Products (SCCP), the Scientific Committee on Health and Environmental Risks (SCHER) and the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), and are made up of external experts. In addition, the Commission relies upon the work of the European Food Safety Authority (EFSA), the European Medicines Evaluation Agency (EMEA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA). SCENIHR Questions concerning emerging or newly-identified risks and on broad, complex or multi- disciplinary issues requiring a comprehensive assessment of risks to consumer safety or public health and related issues not covered by other Community risk-assessment bodies. In particular, the Committee addresses questions related to potential risks associated with interaction of risk factors, synergic effects, cumulative effects, antimicrobial resistance, new technologies such as nanotechnologies, medical devices, tissue engineering, blood products, fertility reduction, cancer of endocrine organs, physical hazards such as noise and electromagnetic fields and methodologies for assessing new risks.
    [Show full text]
  • Antiseptics and Disinfectants: Activity, Action, and Resistance
    CLINICAL MICROBIOLOGY REVIEWS, Jan. 1999, p. 147–179 Vol. 12, No. 1 0893-8512/99/$04.0010 Copyright © 1999, American Society for Microbiology. All Rights Reserved. Antiseptics and Disinfectants: Activity, Action, and Resistance 1 2 GERALD MCDONNELL * AND A. DENVER RUSSELL STERIS Corporation, St. Louis Operations, St. Louis, Missouri 63166,1 and Welsh School of Pharmacy, Cardiff University, Cardiff CF1 3XF, United Kingdom2 INTRODUCTION .......................................................................................................................................................148 DEFINITIONS ............................................................................................................................................................148 MECHANISMS OF ACTION ...................................................................................................................................148 Introduction.............................................................................................................................................................148 General Methodology .............................................................................................................................................148 Alcohols ....................................................................................................................................................................151 Aldehydes .................................................................................................................................................................151
    [Show full text]
  • Chloroxylenol UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C
    United States Prevention, Pesticides EPA 738-R-94-032 Environmental Protection And Toxic Substances September 1994 Agency (7508W) Reregistration Eligibility Decision (RED) Chloroxylenol UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460 OFFICE OF PREVENTION, PESTICIDES AND TOXIC SUBSTANCES CERTIFIED MAIL Dear Registrant: I am pleased to announce that the Environmental Protection Agency has completed its reregistration eligibility review and decisions on the pesticide chemical case chloroxylenol which includes the active ingredients chloroxylenol. The enclosed Reregistration Eligibility Decision (RED) contains the Agency's evaluation of the data base of these chemicals, its conclusions of the potential human health and environmental risks of the current product uses, and its decisions and conditions under which these uses and products will be eligible for reregistration. The RED includes the data and labeling requirements for products for reregistration. To assist you with a proper response, read the enclosed document entitled "Summary of Instructions for Responding to the RED". This summary also refers to other enclosed documents which include further instructions. You must follow all instructions and submit complete and timely responses. The first set of required responses are due 90 days from the date of this letter. The second set of required responses are due 8 months from the date of this letter. Complete and timely responses will avoid the Agency taking the enforcement action of suspension against your products. If you have questions on the product specific data requirements or wish to meet with the Agency, please contact the Special Review and Reregistration Division representative Yvonne Brown at (703) 308-8073. Sincerely yours, Peter Caulkins, Acting Director Special Review and Reregistration Division Enclosures SUMMARY OF INSTRUCTIONS FOR RESPONDING TO THE REREGISTRATION ELIGIBILITY DECISION (RED) 1.
    [Show full text]
  • Investigations of the Effect of Some Antibacterial Agents on a Bacteriophage
    1. INVESTIGATIONS OF THE EFFECT OF SOME ANTIBACTERIAL AGENTS ON A BACTERIOPHAGE. A THESIS submitted by WILLIAM ROBERT LAING BROWN for the degree of DOCTOR OF PHILOSOPHY in the UNIVERSITY OF LONDON. School of Pharmacy, University of London. April 1962. 2. ABSTRACT. The effects on coliphage T6r of 11 commonly used chemical antibacterial agents have been examined. The effect of the agents on the multiplication of the phage was shown by their effect on the mass lysis of fluid cultures of the host by the phage. Only aminacrine hydrochloride and sodium lauryl sulphate showed significant inhibition of the growth of the phage at concentrations below those inhibiting the host. For the examination of the effect of the agents on free phage particles, a method of assessment giving precise inactivation time estimates has been applied and two methods of interpreting the results have been compared. Large differences have been shown in the effectiveness of different antibacterial agents in inactivating the free phage. The effect on the inactivation time of changes in concentration of the antibacterial agent has been examined for five of the agents and the regression between log inactivation time and log concentration has been shown to be linear. The dilution coefficients for these agents fell into two distinct groups, those for ohioramine T and formaldehyde (about 2 and 3 respectively) being very much smaller than those for crystal violet, cetrimide and phenol (about 11,13 and 15 respectively). It has been postulated that this difference in dilution coefficients indicates different mechanisms of inactivation between the two groups and the possible nature of the mechanisms has been discussed.
    [Show full text]
  • 60474 Federal Register/Vol. 82, No. 243/Wednesday, December 20
    60474 Federal Register / Vol. 82, No. 243 / Wednesday, December 20, 2017 / Rules and Regulations DEPARTMENT OF HEALTH AND SUPPLEMENTARY INFORMATION: ingredients are benzalkonium chloride, benzethonium chloride, chloroxylenol, HUMAN SERVICES Table of Contents alcohol (also referred to as ethanol or Food and Drug Administration I. Executive Summary ethyl alcohol), isopropyl alcohol, and A. Purpose of the Final Rule povidone-iodine. Accordingly, FDA 21 CFR Part 310 B. Summary of the Major Provisions of the does not make a GRAS/GRAE Final Rule determination in this final rule for these [Docket No. FDA–2015–N–0101] C. Costs and Benefits six active ingredients for use as OTC RIN 0910–AH40 II. Table of Abbreviations and Acronyms health care antiseptics. The monograph Commonly Used in This Document or nonmonograph status of these six Safety and Effectiveness of Health III. Introduction A. Terminology Used in the OTC Drug ingredients will be addressed, either Care Antiseptics; Topical Antimicrobial Review Regulations after completion and analysis of ongoing Drug Products for Over-the-Counter B. Topical Antiseptics studies to address the safety and Human Use C. This Final Rule Covers Only Health Care effectiveness data gaps of these Antiseptics ingredients or at a later date, if these AGENCY: Food and Drug Administration, IV. Background studies are not completed. HHS. A. Significant Rulemakings Relevant to This rulemaking finalizes the ACTION: Final rule. This Final Rule nonmonograph status of the remaining B. Public Meetings Relevant to This Final 24 active ingredients intended for use in SUMMARY: The Food and Drug Rule health care antiseptics identified in the Administration (FDA, the Agency, or C.
    [Show full text]